I. Gauthier

发表

A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

A. Oza, L. Seymour, L. Siu, 2006, Cancer Chemotherapy and Pharmacology.

Outcomes of intensity‐modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer

L. Dawson, J. Waldron, B. O'Sullivan, 2015, Head & neck.

Chromium Picolinate Toxicity

M. Malone, D. Grabe, J. Cerulli, 1998, The Annals of pharmacotherapy.

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

A. Tinker, K. Gelmon, L. Seymour, 2020, Investigational New Drugs.

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

L. Seymour, K. Ding, F. Shepherd, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.

L. Seymour, R. Livingston, K. Ding, 2007, Lung cancer.

A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.

L. Seymour, M. Tsao, D. Tu, 2020, Lung cancer.

Predictors of sling revision after mid‐urethral sling procedures: a case–control study

D. Hickling, D. Pascali, I. Gauthier, 2018, BJOG : an international journal of obstetrics and gynaecology.

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

L. Seymour, S. Ellard, W. Walsh, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-fluorouracil in Patients with Advanced Colorectal Cancer Cancer Therapy: Clinical

L. Seymour, D. Jonker, E. Chen, 2022 .

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.

L. Seymour, F. Shepherd, D. Tu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

L. Seymour, D. Hedley, M. Moore, 2012, Investigational New Drugs.

Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.

D. Taussky, D. Béliveau-Nadeau, J. Carrier, 2008, International journal of radiation oncology, biology, physics.

IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group

L. Seymour, F. Shepherd, N. Leighl, 2007 .

Jennifer Lipson, A. Clancy, D. Pascali, 2018, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Drug-Food Interactions in Hospitalised Patients

M. Malone, I. Gauthier, 1998, Drug safety.

Comparison of programs for preventing drug-nutrient interactions in hospitalized patients.

S. Aronovitch, M. Malone, T. Lesar, 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer

L. Seymour, D. Jonker, E. Chen, 2009, Clinical Cancer Research.

719 POSTER Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients (pts) with advanced colorectal cancer (CRC)

L. Seymour, D. Jonker, E. Chen, 2007 .